- Home
- RPAY vs NMRA Comparison
RPAY vs NMRA Comparison
Compare RPAY & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPAY | NMRA |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.0M | 424.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RPAY | NMRA |
|---|---|---|
| Price | $3.50 | $2.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $6.81 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,947,000.00 | N/A |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $0.61 |
| 52 Week High | $8.37 | $11.57 |
Technical Indicators
Market Signals| Indicator | RPAY | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 39.45 |
| Support Level | $3.37 | $2.13 |
| Resistance Level | $3.56 | $2.36 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 89.74 | 0.00 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.